BioSpace News Archive

ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), with Toronto Memory Program, Canada’s largest and most experienced memory clinic and site for drug treatment trials in Alzheimer’s disease (AD) has initiated a pilot longitudinal study to assess the level of blood-based biomarkers in early AD with the support of Parexel, one of the world’s leading global clinical research organizations (CROs).

The promise and potential risks of machine learning and other technology will be examined by experts at the 29th Healthcare Risk Management / Patient Safety Conference on Wednesday, March 11, at the New York Marriott Marquis.

Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that the Company has completed enrollment in its 14-week pivotal CONNECT-FX (Clinical study of Cannabidiol (CBD) in Children and Adolescents with Fragile X) trial.

Orchard Therapeutics (Nasdaq: ORTX), a global leader in gene therapy, today announced that members of the management team will present at the following investor conferences in March:

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced its fourth quarter and full year 2019 financial results and highlights:

NEW YORK, Feb. 26, 2020 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced today a strategic collaboration with Southern Research to support the development of a vaccine, TNX-1800* (live modified horsepox virus vaccine for percutaneous administration) to protect against the new coronavirus disease, COVID-19, based on Tonix’s proprietary horsepox vaccine platform. Tonix is developing TNX-801 (live

Topline data on track for 3Q 2020 Dosing Initiated in ReDUX4 Open Label Extension CAMBRIDGE, Mass., Feb. 26, 2020 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that it has completed patient enrollment in ReDUX4, its double blind, placebo-controlled, international Phase 2b trial evaluating the efficacy and safety of losmapim

-- Reported favorable interim data from Phase 1/2 study of M254 in ITP, supporting expansion of Part B; expect to report updated data in Q2 2020 and launch additional Phase 2 study in CIDP in Q4 2020 -- -- Target enrollment completed in nipocalimab Phase 2 Vivacity-MG study; top-line proof-of-concept results expected in Q3 2020 -- -- Expanded pipeline with nomination of M267, a new SIFbody development candidate targeting CD38; plan to initiate IND-enabling studies in 2020 -- -- Ended 2

CAMBRIDGE, Mass. , Feb. 26, 2020 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Christopher K. Mirabelli , Ph.D., Chairman, President and Chief Executive Officer, Douglas E. Onsi , Chief Financial Officer, and Cynthia Sirard , MD, Vice President, Clinical R

2019 revenues nearly doubled to more than $1.1 billion Exceeded improved 2019 guidance 2020 guidance reflects investment in strategic priorities Webcast today, February 26, 2020, at 11:30 a.m. Eastern Time